title: Molecular pathogenesis of malignant mesothelioma.
abstract: Malignant mesothelioma is a rare, highly aggressive cancer arising from mesothelial cells that line the pleural cavities. Approximately 80% of mesothelioma cases can be directly attributed to asbestos exposure. Additional suspected causes or co-carcinogens include other mineral fibres, simian virus 40 (SV40) and radiation. A mesothelioma epidemic in Turkey has demonstrated a probable genetic predisposition to mineral fibre carcinogenesis and studies of human tissues and animal models of mesothelioma have demonstrated genetic and epigenetic events that contribute to the multistep process of mineral fibre carcinogenesis. Several growth factors and their receptors have a significant role in the oncogenesis, progression and resistance to therapy of mesothelioma. Epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and insulin-like growth factor (IGF) have been shown as targets for therapy based on promising preclinical data. However, clinical trials of tyrosine kinase inhibitors in mesothelioma have been disappointing. Bcl-XL is an important antiapoptotic member of the Bcl-2 family and is overexpressed in several solid tumours, including mesothelioma. Reduction of Bcl-XL expression in mesothelioma induces apoptosis and engenders sensitisation to cytotoxic chemotherapeutic agents. Pharmacological inhibitors of antiapoptotic Bcl-2 family members continue to undergo refinement and have shown promise in mesothelioma.
authors.affiliation: Texas A&M Health Science Center College of Medicine, Temple, TX 76508, USA. prascoe@swmail.sw.org
authors.forename: Philip A
authors.initials: PA
authors.lastname: Rascoe
authors.forename: Daniel
authors.initials: D
authors.lastname: Jupiter
authors.forename: Xiaobo
authors.initials: X
authors.lastname: Cao
authors.forename: James E
authors.initials: JE
authors.lastname: Littlejohn
authors.forename: W Roy
authors.initials: WR
authors.lastname: Smythe
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy / Q000209:etiology / Q000235:genetics* / Q000473:pathology*; D051020:bcl-X Protein / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
chemical_list: C494811:BCL2L1 protein, human; D051020:bcl-X Protein